LNP Formulation Manufacturing

Lipid nanoparticle (LNP) formulation is an advanced drug delivery approach used to encapsulate and deliver nucleic acid therapeutics, including oligonucleotides, siRNA, mRNA, and other nucleic acid payloads. By combining different lipid components into nanoscale particles, LNP formulations can help protect nucleic acid payloads from degradation and facilitate their delivery to target cells.

Protheragen provides LNP formulation development and manufacturing services for oligonucleotide drug products, covering formulation screening, lipid composition optimization, process development, LNP characterization, stability evaluation, scale-up, and manufacturing support. Our development strategies can be adapted to the specific characteristics of the nucleic acid payload, intended delivery route, target product profile, and development stage.

Overview of LNP Formulation Manufacturing

Lipid nanoparticles are nanoscale delivery systems composed of multiple lipid components that surround and encapsulate nucleic acid payloads. A typical LNP formulation contains an ionizable lipid, phospholipid or helper lipid, cholesterol, and PEG-lipid, although the composition and ratios can be adjusted according to the payload and intended application. The lipid composition influences particle formation, encapsulation, stability, cellular interaction, and delivery performance.

LNP formulation manufacturing generally involves controlled mixing of the lipid phase and nucleic acid-containing aqueous phase, followed by downstream processing to remove solvents or unincorporated components and adjust the final formulation. Microfluidic mixing and other controlled mixing technologies can be used to regulate particle formation, while processes such as tangential flow filtration (TFF), buffer exchange, concentration, sterile filtration, and filling may be incorporated according to product requirements.

For oligonucleotide drug products, successful LNP formulation development requires control of both formulation composition and process parameters. Particle size, polydispersity index (PDI), encapsulation efficiency, payload integrity, lipid composition, concentration, and stability are among the important quality attributes that may be evaluated during development. The formulation and manufacturing process are optimized to achieve consistent product quality and support transition from early development to clinical and larger-scale manufacturing.

Fig.1 Typical composition of LNPs. (Xu S, et al., 2025)

Our Services

Protheragen provides integrated LNP formulation development and manufacturing services designed to support oligonucleotide drug products from early formulation studies through process development and scale-up.

Key Components of LNP Formulations

LNPs generally contain several functional lipid components, with each component contributing to the formation and performance of the nanoparticle.

• Ionizable Lipids

Ionizable lipids are central components of many nucleic acid LNP formulations. Their ionization behavior can facilitate interaction with nucleic acids during particle formation and contribute to intracellular delivery. Lipid structure and properties can influence encapsulation, particle characteristics, stability, and delivery performance.

• Phospholipids and Helper Lipids

Phospholipids and other helper lipids contribute to the structural organization of LNPs and can influence particle formation and stability. Their selection and concentration may be optimized together with the ionizable lipid and other components.

• Cholesterol

Cholesterol contributes to the structural integrity and physical properties of LNPs. Changes in cholesterol content can influence particle organization, membrane characteristics, stability, and other formulation attributes.

• PEG-Lipids

PEG-lipids can contribute to particle formation and colloidal stability and may influence particle size and interactions with the surrounding environment. The type and amount of PEG-lipid can therefore be important formulation variables.

LNP Critical Quality Attributes

LNP drug products require a product-specific analytical strategy to monitor critical quality attributes throughout formulation development and manufacturing.

The appropriate CQAs and acceptance criteria depend on the LNP composition, nucleic acid payload, dosage form, route of administration, and development stage. Current literature emphasizes that LNP composition, process parameters, and formulation conditions can all affect final drug product quality.

LNP Formulation for Oligonucleotide Therapeutics

LNP technology can be applied to a range of nucleic acid payloads, including siRNA, mRNA, and other oligonucleotide-based therapeutics. For oligonucleotide CDMO programs, formulation development should be tailored to the molecular properties of the payload and the intended therapeutic application.

Why Choose Protheragen

• Integrated Oligonucleotide CDMO Capabilities

Protheragen combines oligonucleotide drug substance, formulation, analytical, process development, and manufacturing capabilities to support LNP-based oligonucleotide programs within an integrated CDMO framework.

• Molecule-Specific Formulation Development

LNP formulation parameters can be tailored according to the characteristics of the oligonucleotide payload, intended delivery route, target product profile, and development stage.

• Formulation-to-Manufacturing Continuity

Formulation screening and process development are considered together with scale-up and manufacturing requirements to support a smoother transition from laboratory development to clinical manufacturing.

• Integrated Analytical and Stability Support

Analytical characterization and stability evaluation provide data for formulation selection, process optimization, and ongoing product quality assessment.

• Scalable Process Development

LNP process development considers critical mixing and downstream processing parameters to support reproducible manufacturing across development scales.

Lipid nanoparticles provide a versatile delivery platform for nucleic acid therapeutics, but successful development requires coordinated control of lipid composition, payload characteristics, formulation parameters, manufacturing processes, and product quality attributes. An integrated development strategy can help establish LNP formulations that are stable, reproducible, and suitable for subsequent scale-up and manufacturing. Protheragen supports oligonucleotide LNP programs across formulation development, process optimization, analytical characterization, stability evaluation, and manufacturing development, helping advance LNP-based drug products from early formulation studies toward clinical development. Contact us to discuss your LNP formulation development and manufacturing requirements.